Staten Biotechnology B.V.

Although Novo Nordisk A/S said in its first-quarter earnings in May that it hoped to further corner the obesity and diabetes markets by 2025, its deal with Prothena Corporation plc to acquire to a

Biopharmaceutical companies raised $19.5bn in venture capital through the third quarter of 2020 and now Pitchbook and the National Venture Capital Association (NVCA) have revealed that the industry br

BioGeneration Ventures (BGV) and Autobahn Labs recently emerged with new sources of funding for the translation of early research into drug development platforms and therapeutic candidates. Naarden, T

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions. Gilead Inks Fibrotic Disease P